Motonobu Osada
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial.
Journal: Hepatology (Baltimore, Md.)
Published: January 23, 2024
Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1.
Journal: Cancer chemotherapy and pharmacology
Published: April 05, 2022
uPA/PAI-1 and EPClin®: Comparison of their impact on the management of intermediate-prognosis breast cancers
Journal: Gynecologie, obstetrique, fertilite & senologie
Published: June 08, 2021
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.
Journal: Targeted oncology
Published: March 19, 2021
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer.
Journal: Journal for immunotherapy of cancer
Published: April 29, 2020
Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 22, 2019
First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.
Journal: Targeted oncology
Published: September 11, 2019
A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: September 30, 2016
Showing 1-8 of 8
Last Updated: 09/26/2026